Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. - Wikidata - awgldk - TriplyDB

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

http://www.wikidata.org/entity/Q50646471

about

Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.A mutation (R826W) in nucleotide-binding domain 1 of ABCC8 reduces ATPase activity and causes transient neonatal diabetes Pharmacogenetic studies update in type 2 diabetes mellitus Carbohydrate-induced secretion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 Infantile onset diabetes mellitus in developing countries - India Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents The Nucleotide-Binding Sites of SUR1: A Mechanistic Model New insights from monogenic diabetes for "common" type 2 diabetes New opportunities: harnessing induced pluripotency for discovery in diabetes and metabolism KATP channels and cardiovascular disease: suddenly a syndrome Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment Pathogenesis of the metabolic syndrome: insights from monogenic disorders Systemic Administration of Glibenclamide Fails to Achieve Therapeutic Levels in the Brain and Cerebrospinal Fluid of Rodents Phase transitions in the multi-cellular regulatory behavior of pancreatic islet excitability Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects.Genetics and pathophysiology of neonatal diabetes mellitus.Undiagnosed MODY: Time for Action A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agen Genetic Analysis and Follow-Up of 25 Neonatal Diabetes Mellitus Patients in China Genome-wide association studies in type 2 diabetes Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases.Human genetics as a model for target validation: finding new therapies for diabetes.Putting the Genome in Context: Gene-Environment Interactions in Type 2 Diabetes.Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene.Molecular diagnosis of neonatal diabetes mellitus using next-generation sequencing of the whole exome.Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk Weak or no association of TCF7L2 variants with Type 2 diabetes risk in an Arab population.Precision diabetes: learning from monogenic diabetes.β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.Clinical and functional characterization of the Pro1198Leu ABCC8 gene mutation associated with permanent neonatal diabetes mellitus Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application.Many faces of monogenic diabetes A 'picturesque' case of transition from subcutaneous to oral treatment in neonatal diabetes Gene-lifestyle interaction and type 2 diabetes: the EPIC interact case-cohort study Design of glucagon-like Peptide-1 receptor agonist for diabetes mellitus from traditional chinese medicine.Neonatal Diabetes: Case Report of a 9-Week-Old Presenting Diabetic Ketoacidosis Due to an Activating ABCC8 Gene Mutation.Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies.

P2860

Q21563368-EFAB7D1A-20FD-4872-9F79-4C310D510106 Q24302959-DC97A980-4E24-40C0-AE3E-9ED2B7A7C0D2 Q24656945-76872817-531B-4CCF-93EC-6CE9EB596BC1 Q26739350-6767440A-9843-4A57-999F-9539FC37E0C6 Q26749211-6212727B-66B3-4D12-9C7C-7A4C2C00F939 Q26750262-7ABABE33-DBA6-4F3C-ADA0-04C0B4C9E168 Q26751138-531917C0-2ABA-42A9-B3E4-B337639FEE2F Q26774807-ED2A4E2A-99D1-4F0F-8DDF-ECC371581A39 Q26795455-3731F141-E76A-410F-9DF6-BE037BC2436B Q26995562-918BA6FB-AE37-4388-B7C4-69823D295632 Q27013265-6E99201F-1CA7-4C92-BDD1-5FB2518EFA57 Q27013756-3188FCE7-E1DE-496D-9EB7-BD3C71F8B32D Q27024024-99896C6B-26C0-4313-9ADB-F88D32601EC1 Q27301271-5D031290-32E0-42B0-8444-F15021E951B3 Q27321061-2DE01587-5C15-40FE-8FB3-ABC1B519BC0A Q27865195-6A03927D-D577-471B-B1C1-7DB1A7BE740B Q27865274-AD572484-EC49-409B-B581-24DC9C7DBFFD Q28083025-E95C00D0-2F7C-48FE-9671-2F99E59971BB Q28552837-4E714B26-537F-4A1C-A719-607DA5FFF923 Q28602730-472DD47D-7A0D-48EC-A6DC-ADE886B1B4A5 Q28752564-BA55F0B5-7C68-465D-AC23-BCC0EC1E0F68 Q29417103-F73D4358-730D-4168-BB38-2B267B877D52 Q30234640-59F9B4C3-3A52-4427-8759-AD396F787215 Q30251394-0B493961-3FFF-4173-99AA-1DEA3905B748 Q30388214-68F56E68-81D8-494E-A3FE-BB3C8F70E765 Q30466668-B907126D-3644-40CC-A495-2A13BE7D8796 Q30478819-F64B89F7-7FB9-4C5A-A41F-37A26F92F104 Q30713822-6B34F63E-85AF-49DC-BECD-2D83FD1BA2D4 Q33348834-7F4C9793-03C7-4B9B-A8E9-6F6FD19C4462 Q33355188-6B8C86F7-3085-46F6-9E80-7EC7BFCA04E0 Q33453490-4095E9D6-6C41-4869-BF18-017203E92DA5 Q33570085-03A35F85-9DB7-4033-B796-D0625A13D158 Q33588879-89FCC8D3-9CC7-4041-B550-3187E163FC7D Q33593963-24BC3CD9-6A05-4A31-A716-04C3540DB185 Q33622236-D2BE1730-5FA8-48DE-96C0-B28B6F621B59 Q33628687-D8B777FB-DCCB-4FDB-AD0E-D80B6D614130 Q33638105-9B9373BA-6885-44D5-8112-166BDA81E8F6 Q33661003-96B4BCF8-B948-4108-8337-7B0CEDFB49B5 Q33693263-B5985AA7-78F8-429D-B865-5D08F08D6316 Q33700991-3676ADA5-0E24-4D58-B2C1-73ED6E6B65E9

P2860

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

http://www.wikidata.org/entity/Q50646471

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Switching from insulin to oral ...... betes due to Kir6.2 mutations.

@en

Switching from insulin to oral ...... betes due to Kir6.2 mutations.

@nl

type

label

Switching from insulin to oral ...... betes due to Kir6.2 mutations.

@en

Switching from insulin to oral ...... betes due to Kir6.2 mutations.

@nl

prefLabel

Switching from insulin to oral ...... betes due to Kir6.2 mutations.

@en

Switching from insulin to oral ...... betes due to Kir6.2 mutations.

@nl

P1433

Q50646471-0B955329-CC3B-41E7-A8D7-64199519A2F8

P1476

Q50646471-C620F67A-18F5-426A-83B0-E96C15F9062C

P2093

Q50646471-033AF861-2BB4-4A9B-B538-F58A89834D00

Q50646471-1C6929DB-7696-4B04-BB3B-77A1CD995F2B

Q50646471-373ECB06-74E5-462D-976F-5BA67A2A6760

Q50646471-4E2443B3-AD69-4260-B6AE-02464CD84BA9

Q50646471-52FDF4EE-8D02-4A30-81FE-2E0E836C9A2A

Q50646471-580657DC-72CB-48D5-8367-60FA883079F1

Q50646471-659AA2D5-D471-4382-8803-AFBEAB10B8FA

Q50646471-8ABF6C8F-9C1A-467C-A69C-CEE89E6060F6

Q50646471-9AC50658-0A55-4E28-9C89-662A0063B316

Q50646471-AC674488-878A-4574-A1A7-D64525650DFB

P304

Q50646471-0F2CD1DE-5CD4-4DE4-94AD-01C610366227

P31

Q50646471-42C7EDD5-B0A7-40C8-9C15-0094ECA3C55D

P356

Q50646471-5CBB8E11-7730-42EE-8AE3-302E5C27EE65

P407

Q50646471-6BFF2EDE-8381-44AC-B91A-52FB489EA005

P433

Q50646471-39B6BC02-E4D2-4046-805C-D50945DFA34E

P478

Q50646471-F36F72F0-40CE-4E81-8EB7-A9F197861D5D

P50

Q50646471-094AF1A1-8C19-48CE-A4A6-CFBE045C9619

Q50646471-2079C556-4704-4DED-9553-302F53F2CC54

Q50646471-276D25B1-5762-48EA-BE77-7B32F05342C7

Q50646471-7FE1B23C-88EE-4BA9-8790-4667748EE9EF

Q50646471-9FF2059D-7F2F-4830-BB3A-B371C4EBFD7F

Q50646471-A862B078-53A6-4ABA-8DF9-C3488F9D2F03

Q50646471-CB24C507-1E33-40DA-A1F7-928A7C52DB77

P577

Q50646471-C7CED6FC-2497-46C1-A8FE-3E85EC475B6B

P698

Q50646471-7A42ACA2-CB75-4A70-B506-E8DB6792A47B

P921

Q50646471-9381BF3F-752D-4C95-B578-FAD25BA075C2

P356

P1433

The New England Journal of Medicine

P1476

Switching from insulin to oral ...... betes due to Kir6.2 mutations.

@en

P2093

Annabelle S Slingerland

http://www.w3.org/2001/XMLSchema#string

Brian Larkin

http://www.w3.org/2001/XMLSchema#string

Ethel Codner

http://www.w3.org/2001/XMLSchema#string

Frances M Ashcroft

http://www.w3.org/2001/XMLSchema#string

Isabelle Flechtner

http://www.w3.org/2001/XMLSchema#string

Iwar Klimes

http://www.w3.org/2001/XMLSchema#string

Jean-Jacques Robert

http://www.w3.org/2001/XMLSchema#string

Julian Shield

http://www.w3.org/2001/XMLSchema#string

Maciej T Malecki

http://www.w3.org/2001/XMLSchema#string

Michel Polak

http://www.w3.org/2001/XMLSchema#string

P304

467-477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA061759

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

355

http://www.w3.org/2001/XMLSchema#string

P50

Andrew Tym Hattersley

Jens Juul Holst

Pål R Njølstad

Sarah E Flanagan

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16885550

http://www.w3.org/2001/XMLSchema#string

P921